[Sign in] [Register]   

EIAab logo

Index > News Center > News list.
Enter your KeyWord (Ex. ELISA Kit, Cuticular Active Peptide Factor, etc)
Search content in infomation.

Progress in targeted therapy of small cell lung cancer

Posted by star on 2017-12-17 17:17:43


       Small cell lung cancer is the most malignant subtype of lung cancer, accounting for about 15% to 20% of lung cancer patients. Unlike non-small cell lung cancer, there are currently no effective targeted therapies for the treatment of small-cell lung cancer due to the fact that targeted therapeutics such as EGFR and ALK are rare in small cell lung cancer. This study found an effective targeted therapy for small cell lung cancer with N-MYC amplification: synergistic inhibition of N-MYC-expanded small cells by the combination of two small molecule inhibitors (JQ1 and ABT-263) Lung cancer growth.

       The team found that the N-MYC-expanded small cell lung cancer cell line is sensitive to the epigenetic drug, the PET bromodomain inhibitor, JQ1. They found that JQ1 is more sensitive to the BCL-2 inhibitor ABT-263 by inhibiting the expression of BIM protein by N-MYC, thereby enabling N-MYC-expanded small cell lung cancer cells. The combined treatment of JQ1 and ABT-263 effectively interferes with the binding of BIM to BCL-2 and MCL-1, thereby allowing BIM to function to induce apoptosis. Researchers further demonstrated that the combination of JQ1 and ABT-263 effectively inhibits the growth of N-MYC-expanded small cell lung cancer xenografts in a mouse model of small cell lung cancer xenografts. Research work shows that the combined use of JQ1 and ABT-263 may be an effective method for the treatment of N-MYC-amplified small cell lung cancer with potential clinical value.

        Wuhan EIAab Science Co., Ltd is advantage in technology, product, dedicated to provide quality and reliable for all user......

Aspirin or longer life for some patients with colon cancer

Posted by star on 2017-12-13 19:19:26

A Dutch study has shown that taking small doses of aspirin may help to prolong the survival of some patients with colon cancer.

Leiden university medical center researchers underwent surgery between 2001 and 2007, 1000 patients with colon cancer observation analysis, 183 patients found aspirin mortality rate is only 37.2%, did not take aspirin, 817 patients mortality was 48.7%.According to the data, aspirin has certain benefits for colon cancer patients.

Further analysis showed that the adjuvant treatment of aspirin was "most effective" if there was a specific antigen called hla-i in the cancer tissue of colon cancer patients. Conversely, it may not work. Therefore, for patients diagnosed with colon cancer and tumor expression hla-i antigen, the use of aspirin can improve their life expectancy



A new discovery about diabetes treatment

Posted by star on 2017-12-10 17:59:39

       Insulin is a hormone regulating glucose storage. Insulin resistance predisposes to diabetes and metabolic diseases. The cell stops responding to instructions from the hormone. Restoring insulin sensitivity is an effective approach to prevent and treat diabetes and to reduce the major vascular complications. However, currently available insulin sensitizers have significant adverse effects, such as weight gain due to triglyceride accumulation, fractures and hemodynamic changes.

       In a new study, researchers found insulin inhibits glucose production in the liver by inhibiting FOXO1 to activate G6pase and inhibit glucokinase to promote fat generation , respectively. FOXO1 as inhibition of glucose production is predicted to increase lipogenesis. they found SIN3A is the insulin-sensitive FOXO1 corepressor of glucokinase. Genetic ablation of SIN3A abolishes nutrient regulation of glucokinase without affecting other FOXO1 target genes and lowers glycemia without concurrent steatosis. To extend this work, we executed a small-molecule screen and discovered selective inhibitors of FOXO-dependent glucose production devoid of lipogenic activity in hepatocytes.

       The next step is to optimize these compounds in animal experiments, and lay a foundation for clinical trials, they are likely to develop a new method for safer diabetes treatment.



       The activity of fat formation in hepatocytes. In addition to identifying a novel mode of insulin action, these data raise the possibility of developing selectivity modulators, Thus eliminating the adverse effects of insulin sensitizers.


Parkinson’s Disease (PD) Cell Therapy Relieves Symptoms in Monkeys

Posted by star on 2017-11-27 17:07:58

    A study published in Nature shows that symptoms in monkey model of PD by grafting dopamine-producing neurons derived from human induced pluripotent stem cells (IPSCs) into the monkeys’ brains.

    Kyoto University neurosurgeon Jun Takahashi and colleagues generated eight IPSC lines from skin or blood cells collected from seven human subjects—three with PD and four without—and derived dopaminergic progenitors from these cell lines. Then, the researchers grafted the reprogrammed cells into the brains of 2- to 3-year-old-male cynomolgus monkeys that had been treated with the neurotoxin MPTP, which kills dopamine-releasing neurons and result in PD-like movement defects.


     The seven monkeys shows a 40% to 50% improvement in symptoms compared to vehicle-injected controls, such as decreases in tremors and increases in spontaneous movements . The authors confirmed that cells derived from both PD patients and healthy donors made dopamine in vivo, at levels about half that of cells in normal monkeys.

     Next steps may be the researches about safety and efficiency of the cells which will be work in the model. Then we get closer ever in the cell therapy for Parkinson’s disease (PD).


How to determine protein stablity

Posted by star on 2017-11-22 17:39:06

     Protein stability is a major concern for biotechnology, food industries, pharmaceuticals, and academic scientists. A common goal that many in vitro protein studies strive for is the creation of an environment in which protein samples can stably retain native conformations. If proteins of interest adopt non-native congregating structures, normal function may be lost. Protein stability is essential for expressing, purifying, and storing proteins and is needed for functional studies using native and recombinant proteins.


      Processes ranging from large-scale industrial protein production and high throughput screening to the more specific pharmaceutical protein-drug interactions and protein crystallization can be impacted. Conditional factors such as buffer pH, salts, mechanical agitation, and temperature are just some of the more common causes of undesired protein aggregation. Protein stability screening is essential as working with proteins can often be challenging and a time-consuming process.


Page 4 of 75
Hot Genes
ALCAM ACE KSR2 ASPRO C19orf80 Gdf5 Trap1a Atf2
Top Searches
Ubiquitin ELISA Ubiquitin-protein ligase Asprosin metalloproteinase TRAP1A Tumor necrosis vitamin d
Why choose EIAAB
Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
Further Information
About us Protein center Bank account Distributors Terms & Conditions Career

Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab